等待開盤 04-02 09:30:00 美东时间
0.000
0.00%
NEW YORK, Nov. 13, 2025 /PRNewswire/ -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholder...
2025-11-14 06:30
Evoke Pharma (NASDAQ:EVOK) reported quarterly losses of $(0.45) per share which met the analyst consensus estimate. This is a 52.13 percent increase over losses of $(0.94) per share from the same period last year. The
2025-11-13 20:14
Evoke Pharma reported a 61% year-over-year increase in third-quarter 2025 net product sales to $4.3 million. The company has entered into an agreement to be acquired by QOL Medical for $11.00 per share in cash. Additionally, the patent for Gimoti, its nasal spray for diabetic gastroparesis, has been extended to November 2038. Despite higher expenses, the company remains focused on growth and expanded distribution. The tender offer for the acquisi...
2025-11-13 12:00
Evoke Pharma Inc. has filed an initial statement of beneficial ownership with the U.S. Securities and Exchange Commission, naming Roger M. Klein as the beneficial owner. The full filing can be accesse...
2025-11-07 05:11
Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 Wall Street's main indexes slipped...
2025-11-05 02:55
Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 Wall Street's main indexes slipped...
2025-11-04 23:47
Evoke Pharma surges after QOL Medical announces $11 cash acquisition, a 140% premium, expected to close by the end of 2025.
2025-11-04 23:20
Gainers Evoke Pharma (NASDAQ:EVOK) shares moved upwards by 134.4% to $10.76 dur...
2025-11-04 20:06
Evoke Pharma Inc: Proposed Deal for for $11.00 per Share in Cash at Closing
2025-11-04 20:01
QOL Medical to acquire Evoke Pharma for $11.00 per share in cash, representing a 139.7% premium to Evoke's recent stock price. The deal, expected to close by late 2025, values Evoke's GIMOTI treatment for diabetic gastroparesis. Evoke and QOL Medical CEOs highlight strategic alignment and mutual benefits, with QOL Medical bringing commercial expertise to expand GIMOTI's reach. The transaction, approved by both boards, is financed with QOL Medical...
2025-11-04 12:00